by David Wallace Two-year results from the Phase 3 SURPASS-ET trial suggest that earlier initiation of ropeginterferon alfa-2b may provide deeper molecular responses and more durable disease control for some patients with high-risk essential thrombocythemia (ET). The findings were presented by Harinder Gill, MD, at the 2026 European Hematology Association Congress in Stockholm. What Did […]